Εμφάνιση απλής εγγραφής

dc.creatorNtelis K., Bogdanos D., Dimitroulas T., Sakkas L., Daoussis D.en
dc.date.accessioned2023-01-31T09:40:50Z
dc.date.available2023-01-31T09:40:50Z
dc.date.issued2019
dc.identifier10.1007/s11926-019-0815-z
dc.identifier.issn15233774
dc.identifier.urihttp://hdl.handle.net/11615/77337
dc.description.abstractPurpose of Review: Platelets are no longer recognized solely as cell fragments regulating hemostasis. They have pleiotropic functions and they are linked directly or indirectly with the three cornerstones of systemic sclerosis (SSc): vasculopathy, autoimmunity, and fibrosis. In this review, we summarize the current knowledge on the potential role of platelets in the pathogenesis of SSc. Recent Findings: Experimental evidence suggests that vasculopathy, a universal and early finding in SSc, may activate platelets which subsequently release several profibrotic mediators such as serotonin and transforming growth factor β (TGFβ). Platelets may also cross-react with the endothelium leading to the release of molecules, such as thymic stromal lymphopoietin (TSLP), that may trigger fibrosis or sustain vascular damage. Finally, activated platelets express CD40L and provide costimulatory help to B cells, something that may facilitate the breach in immune tolerance. Summary: Preclinical studies point to the direction that platelets are actively involved in SSc pathogenesis. Targeting platelets may be an attractive therapeutic approach in SSc. © 2019, Springer Science+Business Media, LLC, part of Springer Nature.en
dc.language.isoenen
dc.sourceCurrent Rheumatology Reportsen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85062401637&doi=10.1007%2fs11926-019-0815-z&partnerID=40&md5=c2e2d7aec33d3ced4e9eda4370999e50
dc.subjectacetylsalicylic aciden
dc.subjectCD40 liganden
dc.subjectclopidogrelen
dc.subjectconnective tissue growth factoren
dc.subjectcytokineen
dc.subjectdipyridamoleen
dc.subjecthigh mobility group B1 proteinen
dc.subjecthydroxychloroquineen
dc.subjectifetrobanen
dc.subjectiloprosten
dc.subjectplaceboen
dc.subjectplatelet derived growth factoren
dc.subjectprotein VEGF165ben
dc.subjectriociguaten
dc.subjectserotoninen
dc.subjecttergurideen
dc.subjectthymic stromal lymphopoietinen
dc.subjecttoll like receptor 4en
dc.subjecttransforming growth factor betaen
dc.subjecttumor necrosis factor ligand superfamily member 12en
dc.subjectunclassified drugen
dc.subjectvasculotropinen
dc.subjecttransforming growth factor betaen
dc.subjectvasculotropin Aen
dc.subjectantigen expressionen
dc.subjectautoimmunityen
dc.subjectB lymphocyteen
dc.subjectblood vessel injuryen
dc.subjectcontrolled clinical trial (topic)en
dc.subjectcross reactionen
dc.subjectcytokine releaseen
dc.subjectearly diagnosisen
dc.subjectfinger ulceren
dc.subjecthumanen
dc.subjectimmunological toleranceen
dc.subjectmulticenter study (topic)en
dc.subjectpathogenesisen
dc.subjectphase 2 clinical trial (topic)en
dc.subjectphase 3 clinical trial (topic)en
dc.subjectpulmonary hypertensionen
dc.subjectregulatory T lymphocyteen
dc.subjectReviewen
dc.subjectserotonin releaseen
dc.subjectsystemic sclerosisen
dc.subjectthrombocyte activationen
dc.subjectvascular diseaseen
dc.subjectvascular endotheliumen
dc.subjectvascular fibrosisen
dc.subjectautoimmunityen
dc.subjectblooden
dc.subjectfibrosisen
dc.subjectinflammationen
dc.subjectphysiologyen
dc.subjectsystemic sclerosisen
dc.subjectthrombocyteen
dc.subjectAutoimmunityen
dc.subjectBlood Plateletsen
dc.subjectFibrosisen
dc.subjectHumansen
dc.subjectInflammationen
dc.subjectScleroderma, Systemicen
dc.subjectTransforming Growth Factor betaen
dc.subjectVascular Endothelial Growth Factor Aen
dc.subjectCurrent Medicine Group LLC 1en
dc.titlePlatelets in Systemic Sclerosis: the Missing Link Connecting Vasculopathy, Autoimmunity, and Fibrosis?en
dc.typeotheren


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής